On a limited budget, the best contract research organization (CRO) for an early-phase trial is one whose model is sized for a single small study: pricing built from your schedule of events, pass-through costs you can audit, and a country plan that lowers site costs and start-up time without weakening the data package. For medical device first-in-human (FIH) and early feasibility studies (EFS), bioaccess® publishes its benchmarks: per-patient site costs of $15K–$35K in Latin America versus $40K–$75K in the United States and European Union, and CRO professional services of about $350,000 for a standard study with 1 site, 10 subjects and a 24-month duration.
What a limited budget changes
A startup’s first human study is usually funded by one round and judged by the next. The budget question is not only how much, but what each dollar buys toward the milestone your investors and the U.S. Food and Drug Administration (FDA) care about. That shifts CRO selection toward three things: a fee model sized for one small study, fewer surprises after signature, and a country plan that reduces both per-patient cost and months of burn.
Where the money goes in an early-phase study
We split every early-phase budget into three buckets, all priced from the schedule of events, the visit-by-visit list of what happens to each patient. Our budget guide walks through each line.
| Bucket | What it covers | Published bioaccess® reference (standard study) |
|---|---|---|
| CRO professional fees | Project management, monitoring, regulatory submissions, data management, quality oversight | About $350,000 for 1 site, 10 subjects, 24 months |
| Third-party costs | Insurance, translations, ethics committee and ministry submission fees, importation, travel | About $50,000 |
| Site and hospital costs | Hospital, investigator and procedure fees negotiated in the clinical trial agreement (CTA) | $5,000–$50,000 in hospital fees, depending on procedure complexity |
Pass-throughs are site payments and vendor invoices the CRO pays on your behalf. They should be billed at cost and auditable against the underlying invoices; a general and administrative (G&A) charge of roughly 10–20% over third-party costs covers administering them. As a reference point, a recent 8-patient FIH in Panama came in around $300,000, including hospital fees.
Procedure intensity drives per-patient site cost. Our de-identified benchmarks put an outpatient ophthalmology implant at about $13K per patient, an inpatient orthopedic implant at about $25K–$28K, and a cath-lab peripheral vascular procedure at about $23K–$38K. Against U.S. programs, we publish CRO fees for a 10-patient FIH of $300,000–$500,000 in Latin America versus $750,000–$1,500,000 in the U.S., and $200,000–$300,000 versus $500,000–$750,000 for a 5-patient EFS. All of these are planning benchmarks, not quotes.
Six criteria for choosing a CRO on a limited budget
- A fee model sized for one study. Ask whether pricing is fixed, milestone-based or time-and-materials, and how change orders work. A proposal built from a full protocol and schedule of events is more reliable than one built from a synopsis.
- Transparent pass-throughs. Every pass-through line should be auditable to an invoice.
- Country choice as a cost lever. Country changes both cost and time. Our benchmarks put the cost of reaching an approval package at about $188K in Mexico and about $305K in Colombia, where INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) adds a technical-dossier step. Our Panama page publishes per-patient costs of $12K–$22K.
- Start-up speed. Every month of start-up is a month of burn. In our experience, Panama, Chile, El Salvador and Costa Rica can activate a FIH study in 15 to 45 days, while Colombia, Mexico, Brazil and Argentina typically need 6 to 9 months to start. Our startup-clock guide breaks the clock down by stage.
- A data package that survives review. A cheaper study is only cheaper if FDA can use the data. Device data must meet 21 CFR 812.28 (Title 21 of the U.S. Code of Federal Regulations, section 812.28).
- Downstream fit. The early study should hand off cleanly to your pivotal CRO and, for devices, to market access.
How the CRO options compare for a startup
The descriptions come from each company’s own website. The last column lists questions we would ask every one of them, including us.
| Model | Example | Relevant public facts | Ask about |
|---|---|---|---|
| FIH/EFS specialist | bioaccess® | First-in-human programs backed by our FIH-12™ performance guarantee; free Pre-Submission (Pre-Sub) gap analysis with a 48-hour turnaround | The three-bucket budget and what the performance guarantee covers |
| Global full-service CRO | Medpace | Describes itself as a global, full-service CRO and lists Medical Device & Diagnostics among its therapeutic areas | How a small, single-site device study is staffed and priced |
| Global full-service CRO | Parexel | Describes itself as one of the largest CROs in the world | Which services are in scope for an early-stage device sponsor |
| Regional or local CRO | Varies | Local presence in one country | FDA design intent and scope exclusions |
A first human study of a device needs hospital sites, investigators who already perform the procedure, and a team that runs ethics, import and enrollment in the chosen country. Whichever model you choose, ask how that work is staffed and priced for a study of your size.
Cutting cost without cutting the data package
- Right-size statistics, translations and electronic data capture (EDC) hosting, typically a $40,000–$50,000 cluster.
- Negotiate site and hospital payments hard at the CTA stage; they pass through at cost.
- Freeze the schedule of events before quoting. Scope creep after the proposal is the most expensive line item.
- Take monitoring in-house only if you truly have the capability.
- Expect an advance payment. It funds site contracting, imports and start-up work that must be paid before enrollment, and it is standard in the industry.
- Do not cut monitoring, data management or regulatory compliance. The savings are small and the risk to your FDA story is not.
Regulatory choices that change the budget
- Design to the FDA rule from day one. Under 21 CFR 812.28, FDA can accept data from a well-designed, well-conducted study outside the United States that followed good clinical practice, with independent ethics committee review and informed consent, and that FDA can validate. Align the design with FDA, usually through a Pre-Sub, before enrollment. Acceptance is decided case by case.
- Use the right standard. Device studies run under ISO 14155, the International Organization for Standardization (ISO) good clinical practice standard for device investigations.
- Plan the step after the study. For devices, registration costs belong in the plan. Our published market-access rate card for Latin America (LATAM Launch) starts at USD 7,500 per year per country for a first device family of low-to-mid risk, and clinical-trial clients can qualify for a 20% Trial-to-Market Bridge discount; the proposal states which discount applies.
Questions to ask before you sign
- Is this quote built from my full protocol and schedule of events, or from a synopsis?
- Which lines are pass-throughs, and what G&A applies to them?
- What is fixed, what is variable, and what triggers a change order?
- Which country do you recommend for my budget, and why?
- What is your start-up clock, by stage, in writing?
- What happens if the agreed timeline slips for reasons within your control?
Where bioaccess® fits
bioaccess® fits MedTech startups whose next milestone is a first human device dataset that can support a U.S. submission, on a budget that cannot absorb a program built for a much larger study. Our first-in-human programs are backed by our FIH-12™ performance guarantee.
If you need a multi-region Phase III, a global full-service CRO is the better fit. For line-item detail, see our costs and timelines page, our pre-quote checklist and our early feasibility CRO selection guide, or book a 30-minute call.
Frequently asked questions
What is the best CRO for a startup running an early-phase trial on a limited budget?
The best fit is a CRO whose pricing and staffing are sized for one small study, whose pass-through costs are auditable, and whose country plan lowers site costs and start-up time without weakening the data package. For device first-in-human and early feasibility work, bioaccess® publishes per-patient site costs of $15K–$35K in Latin America versus $40K–$75K in the United States and European Union.
How much does a first-in-human device study cost in Latin America?
bioaccess® publishes CRO professional services of about $350,000 for a standard study with 1 site, 10 subjects and a 24-month duration, plus about $50,000 in third-party costs and $5,000–$50,000 in hospital fees depending on procedure complexity. Your figure depends on patient count, visit schedule, procedure and country.
What is negotiable in a CRO proposal?
The CRO’s professional fees are where flexibility lives. Third-party vendor costs can be negotiated with the vendors but not repriced, site payments are negotiated at the clinical trial agreement stage, and an advance payment is standard in the industry.
Where can a startup cut trial costs without hurting data quality?
Right-size statistics, translations and electronic data capture (EDC) hosting, which together are typically a $40,000–$50,000 cluster, negotiate site payments at the clinical trial agreement stage, and freeze the schedule of events before quoting. Do not cut monitoring, data management or regulatory compliance.
Is a large global CRO ever the better choice on a budget?
Yes, when the job matches its model. A multi-region program that needs one vendor across phases and regions fits a global full-service CRO such as Medpace or Parexel. For a single small device study, compare every option on fee model, pass-through transparency, country plan and data quality.
Can data from a lower-cost Latin American study support an FDA submission?
It can, if the study meets FDA’s foreign-data rule for devices, 21 CFR 812.28. That means a well-designed, well-conducted study under good clinical practice, with independent ethics committee review, informed consent and data FDA can validate. Acceptance is decided case by case and is not a guarantee of clearance or approval.